2'-DEOXY-2',2'-DIFLUOROCYTIDINE 5'-(9E)-OCTADEC-9-ENOATE

Lung Cancer

Clovis Oncology, Inc.Small moleculePhase 1Dormant

C

37/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 65/ 100

Competitive context

304 Active assets in the Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Carboplatin SystImmune Inc.	Phase 4	BB
CIS-DIAMMINEDICHLOROPLATINUM II University of Vermont	Phase 4	BB
PROPOFOL Kaohsiung Medical University Chung-Ho Memorial Hospital	Phase 4	BB
ETOPOSIDE SystImmune Inc.	Phase 3	BB
Nivolumab University of Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

2'-DEOXY-2',2'-DIFLUOROCYTIDINE 5'-(9E)-OCTADEC-9-ENOATE is also rated in:

pancreatic adenocarcinomaDormant

B

Indicative ·

61 / 100

pancreatic adenocarcinomaDormant

B

Indicative ·

57 / 100

non-small cell lung carcinomaDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.